{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 405761835
| IUPAC_name = ''N''<sup>2</sup>-(3,4-Dichlorobenzoyl-''N'',''N''-dipentyl-α-glutamine
| image = Lorglumide.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 97964-56-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 3960
| IUPHAR_ligand = 891
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = LAD1UQ73BE
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 24938
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 88305
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 3823

<!--Chemical data-->
| C=22 | H=32 | Cl=2 | N=2 | O=4 
| molecular_weight = 459.406 g/mol
| synonyms = <small>4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid</small>
| smiles            = CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = IEKOTSCYBBDIJC-UHFFFAOYSA-N
}}

'''Lorglumide''' ('''CR-1409''') is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a [[cholecystokinin antagonist]],<ref>{{cite journal | pmid = 3440035| year = 1987| author1 = Makovec| first1 = F| title = Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists| journal = Arzneimittel-Forschung| volume = 37| issue = 11| pages = 1265–8| last2 = Bani| first2 = M| last3 = Cereda| first3 = R| last4 = Chisté| first4 = R| last5 = Pacini| first5 = M. A.| last6 = Revel| first6 = L| last7 = Rovati| first7 = L. A.| last8 = Rovati| first8 = L. C.| last9 = Setnikar| first9 = I}}</ref> with fairly high selectivity for the [[Cholecystokinin A receptor|CCK<sub>A</sub>]] subtype.<ref>{{cite journal | pmid = 16150104| year = 2005| author1 = González-Puga| first1 = C| title = Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: Synergism with pharmacological levels of melatonin| journal = Journal of Pineal Research| volume = 39| issue = 3| pages = 243–50| last2 = García-Navarro| first2 = A| last3 = Escames| first3 = G| last4 = León| first4 = J| last5 = López-Cantarero| first5 = M| last6 = Ros| first6 = E| last7 = Acuña-Castroviejo| first7 = D| doi = 10.1111/j.1600-079X.2005.00239.x}}</ref> It has been suggested as a potential treatment for a variety of gastrointestinal problems including [[stomach ulcer]]s, [[irritable bowel syndrome]], [[dyspepsia]], [[constipation]] and [[pancreatitis]], as well as some forms of [[cancer]], but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.<ref>{{cite journal | pmid = 10213792| year = 1999| author1 = De Tullio| first1 = P| title = Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists)| journal = Current medicinal chemistry| volume = 6| issue = 6| pages = 433–55| last2 = Delarge| first2 = J| last3 = Pirotte| first3 = B}}</ref><ref>{{cite journal | pmid = 11060666| year = 2000| author1 = De Tullio| first1 = P| title = Therapeutic and chemical developments of cholecystokinin receptor ligands| journal = Expert Opinion on Investigational Drugs| volume = 9| issue = 1| pages = 129–46| last2 = Delarge| first2 = J| last3 = Pirotte| first3 = B| doi = 10.1517/13543784.9.1.129}}</ref><ref>{{cite journal | pmid = 12789687| year = 2003| author1 = Herranz| first1 = R| title = Cholecystokinin antagonists: Pharmacological and therapeutic potential| journal = Medicinal Research Reviews| volume = 23| issue = 5| pages = 559–605| doi = 10.1002/med.10042}}</ref><ref>{{cite journal | pmid = 17997137| pmc = 2186776| year = 2007| author1 = Berna| first1 = M. J.| title = Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential| journal = Current Opinion in Pharmacology| volume = 7| issue = 6| pages = 583–92| last2 = Tapia| first2 = J. A.| last3 = Sancho| first3 = V| last4 = Jensen| first4 = R. T.| doi = 10.1016/j.coph.2007.09.011}}</ref> 

== References ==
{{Reflist}}


{{Drugs for functional gastrointestinal disorders}}
{{Drugs for peptic ulcer and GORD}}
{{Neuropeptidergics}}

[[Category:Cholecystokinin antagonists]]
[[Category:Chloroarenes]]
[[Category:Benzamides]]